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Lynch syndrome confers an increased risk for urothelial carcinoma (UC).
Molecular subtypes may be relevant to prognosis and therapeutic possibili-
ties, but have to date not been defined in Lynch syndrome-associated
urothelial cancer. We aimed to provide a molecular description of Lynch
syndrome-associated UC. Thus, Lynch syndrome-associated UCs of the
upper urinary tract and the urinary bladder were identified in the Danish
hereditary nonpolyposis colorectal cancer (HNPCC) register and were tran-
scriptionally and immunohistochemically profiled and further related to
data from 307 sporadic urothelial carcinomas. Whole-genome mRNA
expression profiles of 41 tumors and immunohistochemical stainings
against FGFR3, KRT5, CCNB1, RB1, and CDKN2A (p16) of 37 tumors
from patients with Lynch syndrome were generated. Pathological data,
microsatellite instability, anatomic location, and overall survival data were
analyzed and compared with sporadic bladder cancer. The 41 Lynch syn-
drome-associated UC developed at a mean age of 61 years with 59%
women. mRNA expression profiling and immunostaining classified the
majority of the Lynch syndrome-associated UC as urothelial-like tumors
with only 20% being genomically unstable, basal/SCC-like, or other sub-
types. The subtypes were associated with stage, grade, and microsatellite
instability. Comparison to larger datasets revealed that Lynch syndrome-
associated UC shares molecular similarities with sporadic UC. In
conclusion, transcriptomic and immunohistochemical profiling identifies a
predominance of the urothelial-like molecular subtype in Lynch syndrome
and reveals that the molecular subtypes of sporadic bladder cancer are rele-
vant also within this hereditary, mismatch-repair defective subset.
1. Introduction
Heredity in upper urinary tract urothelial carcinoma
particularly relates to the Lynch syndrome, which is
caused by germline mutations in the mismatch repair
(MMR) genes MLH1, MSH2, MSH6, or PMS2. The
highest risks apply to colorectal cancer (50–80% life-
time risk) and endometrial cancer (40–60% lifetime
Abbreviations
GU, genomically unstable; HNPCC, hereditary nonpolyposis colorectal cancer; IHC, immunohistochemistry; MMR, mismatch repair; MSI,
microsatellite instability; TMA, tissue microarray; UC, urothelial carcinoma; Uro, urothelial-like; UTUC, upper urinary tract urothelial
carcinoma.
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risk), but efficient surveillance and prophylactic risk
reduction procedures have led to improved survival
rates and prolonged life expectancy. This implies a
longer time at-risk of developing less common tumor
types such as urothelial cancer (UC) (J€arvinen et al.,
2009). We have recently shown a significantly
increased incidence of UC in the Danish Lynch syn-
drome population, which applies to both genders and
increases with age (Therkildsen et al., 2017). The
upper urinary tract urothelial carcinomas (UTUC) are
particularly overrepresented in Lynch syndrome with
cumulative risks estimated between 6.0 and 15.4% for
UTUC and 2.4–9.0% for bladder UC (Engel et al.,
2012; van der Post et al., 2010; Watson et al., 2008).
Development of UC in Lynch syndrome is associated
with mutations in the MSH2 gene with such mutations
in 65–70% of the UC in Lynch syndrome (Engel et al.,
2012; Joost et al., 2015; van der Post et al., 2010; Skel-
don et al., 2013).
Urothelial carcinomas of the upper urinary tract
and the urinary bladder are morphologically and bio-
logically similar (Krabbe et al., 2014). Differences in
mutational profiles have been reported in high-grade
tumors with more frequent mutations in FGFR3,
HRAS, and CDKN2B in UTUC and in TP53 and
RB1 in bladder UC (Sanford et al., 2015; Sfakianos
et al., 2015). In assumingly sporadic tumors, defective
mismatch-repair (MMR) is found in 11% of UTUC
and in variable frequencies, most likely reflecting
diverse assessment principles, in bladder UC (Catto
et al., 2003; Metcalfe et al., 2018). Gene expression
profiles have defined recurrent molecular subtypes in
bladder UC and UTUC (Cancer Genome Atlas
Research Network, 2014; Choi et al., 2014; Damrauer
et al., 2014; Moss et al., 2017; Sj€odahl et al., 2012),
but have not been investigated in tumors from patients
with Lynch syndrome. Here, we define molecular sub-
types of UC linked to Lynch syndrome with compar-
ison to a stage-matched cohort of sporadic UC using
both mRNA and immunohistochemically based
expression signatures.
2. Materials and methods
2.1. Patient and tumor selection
Eligible patients with urothelial cancer (UC) were
identified through the national Danish hereditary non-
polyposis colorectal cancer (HNPCC) registry as previ-
ously described (Joost et al., 2015). In brief, 92 UC
had been surgically removed from 65 patients with
Lynch syndrome between 1982 and 2013 of which tis-
sues from 41 unique patients were available for
analysis as no patient with samples from more than
one tumor was available. All samples were investigated
for microsatellite instability (MSI) with 19 tumors
showing an MSI phenotype as previously described
(Joost et al., 2015). The tumors developed in MMR
mutation carriers (n = 40) or in deceased first-degree
relatives, in which gene carrier status could not be
evaluated through tumor analyses (n = 1). Pathologic
re-evaluation was performed, tumor stage was deter-
mined according to the TNM 2009 classification, and
tumor grading was applied using the WHO 1999 and
2004 systems. Surgery included transurethral resections
of bladder cancers and nephroureterectomies for upper
urinary tract tumors. The study was approved by the
Scientific and Ethical Committee at the Capital Region
of Denmark (HD-2007-0032 and H-17001916) and the
Danish Data Protection Agency (2007-58-0015 and
AHH-2017-071).
2.2. RNA extraction and mRNA profiling
Total RNA was extracted from FFPE tissue blocks,
amplified and labeled using the SensationPlus labeling
kit, and hybridized to Gene ST 1.0 Affymetrix
microarrays at the SCIBLU genomics facility in Lund,
Sweden. Raw data are deposited at the Gene Expres-
sion Omnibus repository (GSE104922). RNA subtype
classification of urothelial Lynch syndrome tumors
was compared to a reference dataset of 307 advanced,
subtype classified bladder tumors (GSE83586). Direct
comparison to other large available datasets, such as
TCGA, was not performed due to differences in data
type (microarray versus RNA-Seq, and sample quality
FFPE-RNA versus fresh-frozen-RNA). For details on
mRNA profiling and subtype classification,
Appendix S1.
2.3. Tissue microarrays (TMA) and
immunohistochemistry (IHC)-based subtype
classification
For 36 of 41 tumors, sufficient tumor tissue to obtain
two 1.0-mm tissue cores was available to construct a
TMA. Tumors were classified as urothelial-like (Uro),
basal/SCC-like and genomically unstable (GU) based
on a previously described IHC-classifier (Pradere et al.,
2017). For details Appendix S1.
2.4. Lynch syndrome in sporadic bladder cancer
To investigate undiagnosed Lynch syndrome in spo-
radic bladder cancer, we performed immunostaining
for MLH1, MSH2, and MSH6 in an extended
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population-based cohort (n = 383) (Sj€odahl et al.,
2017) using antibodies against MLH1 (ES05, dilution
1 : 50, Dako, Glostrup, Denmark), MSH2 (FE11,
dilution 1 : 50, Dako), and MSH6 (EP49, dilution
1 : 50, Dako) and the Dako EnvisionTM FLEX+ detec-
tion kit (Dako) following manufacturer’s instruction.
In brief, 5 lm sections were deparaffinized and rehy-
drated and heat-induced epitope retrieval was per-
formed using a PT Link (Dako) for 20 min at pH 9.
The antibody stainings were performed in a Dako
Autostainer Plus (Dako) using the EnvisionTM FLEX+
Mouse or Rabbit LINKER (Dako). Sections were
counter-stained with hematoxylin and eosin, dehy-
drated, and preserved with coverslips using Per-
mountTM mounting medium (Fisher Scientific,
Hampton, NH, USA).
2.5. Statistical analysis
Overall survival (defined as time form surgery to date
of death) for the 41 patients with Lynch syndrome
urothelial cancer was compared to a reference cohort
of sporadic bladder urothelial cancer (Sj€odahl et al.,
2012). To minimize the effect bias from T-stage, identi-
cal proportions of Ta/T1/ ≥ pT2 were achieved by ran-
domly excluding 53 pT1 and one ≥ pT2 tumor, leaving
114 pTa, 42 pT1, and 90 ≥ pT2 tumors in the external
survival dataset. For Kaplan–Meier visualization of
overall survival, data were censored at 150 months,
which affected eight nonevents and one event, all in
the Lynch syndrome subset. Differences in survival
were evaluated using logrank test and univariate Cox
proportional hazard ratio. Associations between clini-
cal characteristics and molecular data were investi-
gated using Fisher’s exact test. Bonferroni corrections
were used whenever relevant.
3. Results
3.1. Patient characteristics
The 41 Lynch syndrome-associated UCs were located
in the bladder (n = 19), the ureter (n = 14), and the
renal pelvis (n = 8) (Table 1). IHC-analysis showed
loss of protein expression corresponding to the dis-
ease-predisposing MMR gene mutation in 98% of the
samples, of which 46% were microsatellite instable
and 54% were microsatellite stable. The majority of
tumors (71%) developed in MSH2 mutation carriers.
The tumors developed at mean age of 61 years (range
36 to 80 years) and with a preference for females
(59%). Tumor stage was pTa or pT1 in 68% of the
bladder cancers and in 59% of the upper urinary tract
tumors. Previous metachronous cancer had developed
in 32 patients and included 32 colorectal cancers, 12
endometrial cancers, and 18 UC.
3.2. Characterization of Lynch syndrome-
associated tumors by gene expression profiling
We performed unsupervised hierarchical clustering of
the Lynch syndrome-associated tumors (Fig. 1), using
the top varying genes (n = 7569). This produced three
major clusters, where Cluster 1 (n = 20) contained the
majority of invasive tumors (> Ta) (4 pTa, 6 pT1, and
10 ≥ pT2). Cluster 2 (n = 11) contained 6 pTa, one
pT1, and four ≥ pT2, and Cluster 3 (n = 10) contained
9 pTa and one ≥ pT2 tumor. The major division in the
clustering was related to tumor stage, which showed
significant difference between clusters (pTa versus
≥ pT1, P < 0.001). Furthermore, 65% of the UTUC
were located in Cluster 1 and 72% of bladder tumors
in Cluster 2 (Fisher’s exact test, P = 0.03). None of
Table 1. Descriptive data of the Lynch syndrome-associated UC.
Description of the clinical and pathological tumor characteristics in
the 41 urothelial carcinomas in patients with Lynch syndrome-
associated UC. MSI = microsatellite instability and MSS =
microsatellite stable tumors according to all five mononucleotide
markers BAT-25, BAT-26, NR-21, NR-24, and MONO-27 used (5).
MSI-low (MSI-L) indicates instability for one marker and MSI-high
(MSI-H) for ≥ two markers.
Stage Numbers (n = 41) %
pTa 19 47
pT1 7 17
pT2 10 24
pT3 5 12
Grade (WHO 1999/2004)
G1/LG 2 5
G2/HG 23 56
G3/HG 16 39
Gene affected
MLH1 5 12
MSH2 29 71
MSH6 7 17
Carrier status
First-degree relative 1 2
Carrier 32 78
Obligate carrier 8 20
MSI status
MSS 22 54
MSI-L 7 17
MSI-H 12 29
Anatomic site
Bladder 19 46
Ureter 14 34
Renal pelvis 8 20
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the clusters were specifically associated with mutations
in MSH6, MLH1, or MSH2, but there was a signifi-
cant difference in the rate of microsatellite instability
(MSI) among the clusters, with Cluster 3 showing the
lowest proportion of MSI (Fisher’s exact test,
P = 0.01). A three-group ANOVA test indicated 806
significant genes (P < 0.01, Bonferroni corrected) with
the majority showing upregulation in Cluster 1. Gene
ontology analysis showed broad enrichment of terms
related to, for example, cell cycle regulation, metabolic
and catabolic processes, and RNA processing
(Table S1). Comparing global mRNA expression
between Lynch syndrome-associated bladder tumors
and upper urinary tract UC revealed no significant dif-
ferences in gene expression patterns using t-test and
SAM analysis (data not shown).
3.3. Lynch syndrome-associated UC in relation to
sporadic bladder cancers
To compare Lynch syndrome-associated and sporadic
UC, we combined mRNA data from the 41 Lynch
syndrome tumors with data from 307 sporadic
advanced bladder cancers (Sj€odahl et al., 2017). Unsu-
pervised hierarchical cluster analysis showed that
Lynch syndrome tumors were distributed among the
sporadic bladder cancers and did not form a distinct
group separated from the main cohort of sporadic
tumors. The Lynch syndrome tumors formed two
aggregations consisting of Cluster 1 tumors and Clus-
ter 3 tumors, respectively (Fig. 2A). Hence, the expres-
sion profiles of Lynch syndrome tumors seem to be
more similar to each other than to sporadic tumors
(Fig. 2A). To examine how the Lynch syndrome sam-
ples related to the molecular subtypes of bladder can-
cer, we arranged the reference dataset according to
molecular subtype (Sj€odahl et al., 2017) and inserted
the Lynch syndrome UC into the dataset by placing
them adjacent to the most similar sporadic tumor
(Fig. 2B). The majority (33/41) grouped with bladder
cancer of the Uro subtypes (18 UroA-Prog, two UroC,
six Uro-Inf, and seven UroB) (Fig. 2B). The pro-
gressed UroA group (UroA-Prog) contained the
majority of lower stage tumors in the reference data-
set, and accordingly, 9 of 10 low-stage Cluster 3 Lynch
syndrome tumors grouped with this subtype. Among
Fig. 1. Gene expression analysis of Lynch syndrome-associated UC. Gene expression data from 41 Lynch syndrome-associated UC were
median centered and subjected to hierarchical clustering analysis (Ward’s algorithm, Pearson correlation). The three clusters identified were
associated with tumor stage, grade (WHO 1999), and microsatellite instability, but not with affected gene. Heatmaps show three patterns
of differentially expressed genes identified by three-group ANOVA between Cluster 1 and Cluster 3. MSS = microsatellite stable; MSI-low
(MSI-L) indicates instability for one marker and MSI-high (MSI-H) for ≥ two markers. UT = Upper urinary tract.
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the remaining eight Lynch syndrome samples, three
grouped with the genomically unstable (GU), four
with the basal/SCC-like, and one with mesenchymal-
like bladder tumors. No significant difference in stage
(pTa/pT1 versus ≥ pT2) or affected MMR gene of
Lynch syndrome tumors was observed when grouped
by subtype. Similarly, we found no significant differ-
ence in the rate of MSI between cases clustering with
the UroA-Prog (MSI = 6, MSS = 11) versus those
clustering with the other Uro subtypes (MSI = 6,
MSS = 4, P = 0.3), nor when comparing the UroA-
Prog group to all other Lynch syndrome cases
(MSI = 13, MSS = 10, P = 0.2).
3.4. Molecular pathological analysis of Lynch
syndrome-associated urothelial carcinomas
The TMA sections were stained for markers associated
with molecular subtype, that is, antibodies for
FGFR3, CCNB1, KRT5, RB1, and CDKN2A (p16),
and examined for maintained urothelial-like stratifica-
tion of cell layers. The results were strongly reminis-
cent of sporadic bladder cancer, and 21 of 37 cases
showed urothelial-like histology, low stage, and grade,
thus sharing characteristics with the Uro subtype. This
was supported molecularly by stratified expression of
basal urothelial markers; for example, KRT5 expres-
sion and proliferation limited to the basal and supra-
basal layers, and high tumor-cell expression of FGFR3
in all cell layers (Fig. 3A). Among the non-Uro
classified cases, six were classified as GU with high
levels of CDKN2A (p16) and CCNB1, while four were
classified as basal/SCC-like due to up-regulation of
KRT5 and downregulation of FGFR3 (Fig. 3B). The
IHC staining did not differ in patterns compared to
sporadic UC. For example, the GU IHC-class con-
tained cases with RB1 loss and showed higher CCNB1
staining than Uro-classified cases (group mean 0.27
versus 0.13, t-test, P = 1.8 e-5) and four of six were of
stage ≥ pT2 (Fig. 3B). The basal/SCC-like cases were
all of stage ≥ pT2 and showed nonstratified KRT5
expression (Fig. 3A,B). The IHC-class corresponded to
the subtype defined by mRNA expression (Fig. 2B) in
the sporadic UC dataset in 69% of the cases (Fig. 3B).
Taken together, these data indicate that UCs in
patients with Lynch syndrome molecularly are compa-
rable to sporadic urinary UC.
3.5. Overall survival for Lynch syndrome-
associated and sporadic urothelial cancer
The 10-year crude survival for Lynch syndrome
patients with UC was 50%, which was similar for
stage-matched sporadic bladder cancer cohort
(n = 246) (Sj€odahl et al., 2012). Univariate analysis
indicated no difference in outcome between the groups
(HR: 1.07 95% CI: 0.63–1.82, logrank-P = 0.81)
(Fig. 4A). Furthermore, fundamental patient charac-
teristics such as gender distribution (Lynch syndrome:
24 females and 17 males; sporadic cancer: 80 females
Fig. 2. Lynch syndrome-associated UC co-segregates with molecular subtypes of sporadic bladder cancer. (A) The 41 Lynch syndrome-
associated UCs were recentered with a cohort of advanced sporadic UC and subjected to hierarchical clustering analysis (Ward’s algorithm,
Pearson correlation). The results indicate that some Lynch syndrome tumors cocluster, but Lynch syndrome UCs are found in all branches
of the cluster dendrogram, indicating that Lynch tumors are not fundamentally different from sporadic UC. (B) Lynch syndrome-associated
UC cases were mapped to bladder cancer molecular subtypes by placing each Lynch syndrome sample next to the sporadic UC sample
with highest correlation (Pearson-r) in the subtype-ordered combined dataset. (Mes-like = mesenchymal-like; Sc/NE = small-cell/
neuroendocrine-like; GU = genomically unstable; Ba/Sq = basal/squamous-like; Inf = infiltrated).
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and 228 males, Fisher’s exact test, P = 4.6 e-5) and
age at diagnosis (60 years for Lynch syndrome and
73.5 years for sporadic cancer; Mann–Whitney,
P = 4.0 e-7) (Fig. 4B) differed significantly between
the two cohorts. Overall survival was not significantly
influenced by MSI status within the MMR-deficient
Lynch syndrome cohort (Fig. 5).
3.6. Lynch syndrome in sporadic advanced
bladder cancer
To investigate whether advanced sporadic bladder
tumors include potentially undiagnosed Lynch
syndrome patients, we performed IHC for MLH1,
MSH2, and MSH6 in a population-based cohort
(n = 383) (Sj€odahl et al., 2017). Only two tumors
(0.5%) showed tumor-specific loss of staining for
MLH1 and MSH6, respectively, suggestive of Lynch
syndrome and thus have a negligible impact on the
results.
4. Discussion
Based on mRNA and IHC profiling, we demonstrate
that Lynch syndrome-associated UC segregates into
three clusters associated with tumor stage, grade, and
Fig. 3. Molecular pathological analysis of Lynch syndrome-associated UC shows strong similarity to sporadic UC phenotypes. (A) Four
examples of 37 analyzed Lynch syndrome-associated UC showing IHC marker profiles typical for the bladder cancer subtypes UroA, UroB,
genomically unstable, and basal/SCC-like. Scale bar, 200 lm. B) IHC-based subtype classification was based on IHC-scores, tumor grade
(WHO1999), and urothelial-like histology. IHC-subtype is shown in relation to tumor stage, tumor grade (WHO1999), Lynch syndrome
cluster (color-coded as in Figure 1), and mRNA subtype (color-coded as in Figure 2B). IHC-phenotype were color-coded as follows;
green = urothelial-like (Uro); blue = genomically unstable (GU); red = basal/SCC-like; gray = missing data.
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MSI status, which represent the main determinants of
the global gene expression pattern (Fig. 1). When ana-
lyzed in the context of sporadic UC, Lynch syndrome-
associated tumors clustered within the established
molecular subtypes and together with sporadic tumors.
Both mRNA-based and IHC-based molecular classifi-
cations resulted in the expected frequencies of molecu-
lar subtypes given the stage distribution in the cohort,
which suggests that the predefined molecular subtypes
dominate over genetic predisposition. At the molecular
pathology level, most tumors demonstrated an urothe-
lial-like (Uro) phenotype with low stage/grade,
retained stratification of basal-intermediate cell layers,
and frequent FGFR3 expression. Among T1 and ≥ T2
cases, some tumors showed typical basal/squamous-
like or genomically unstable phenotypes, confirming
that all the three major UC phenotypes are repre-
sented also in Lynch syndrome. Data that compare
molecular subtypes in UC of the upper and the lower
urinary tract are scarce. In a gene expression study of
12 UTUC and 20 bladder UC, the basal subtype was
suggested to be less frequent in UTUC (Sanford et al.,
2015). Mutations in UTUC and bladder UC differed
only for HRAS, CDKN2B, TP53, RB1, and ARID1A
when investigated in a set of 59 high-grade UTUC and
102 high-grade bladder UC (Sanford et al., 2015; Sfa-
kianos et al., 2015). Gene expression patterns did not
differ between the 19 bladder UC and 22 UTUC in
the present study; however, limited sample size and
heterogeneous stage distribution preclude any firm
conclusions.
The comparison with sporadic UTUC and bladder
cancer revealed a female preponderance and younger
age at first UC diagnosis for patients with Lynch syn-
drome. As previously reported (Pradere et al., 2017),
UC linked to Lynch syndrome develops at a lower age
than sporadic UC with mean 13.5 years earlier age at
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Fig. 4. Patients with Lynch syndrome-associated UC have similar overall survival, but are diagnosed at younger age than patients with
sporadic UC. (A) Kaplan–Meier estimates of overall survival for the 41 Lynch syndrome cases compared to a stage-matched subset of a
cohort of sporadic UC of the bladder. No significant differences were observed (P = 0.81). (B) Histogram showing patients age at first UC
diagnosis for all 41 Lynch syndrome cases and all cases in the sporadic cohort for which this information was available (n = 230). Y-axis is
recalculated to percentages in order to account for large differences in cohort size.
Fig. 5. Overall survival stratified by MSI/MSS. Overall survival for
MSI (blue) and MSS (red) Lynch syndrome-associated tumors
(P = 0.14).
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onset in our study. Lynch syndrome-associated tumor
may have a better response to adjuvant chemotherapy
after radical nephroureterectomy (Hollande et al.,
2014). Long-term outcome is, however, also influenced
by the high frequency of metachronous tumor develop-
ment, which affected 78% of the Lynch syndrome
patients in our study with metachronous development
of 32 colorectal cancers and 18 UC.
Increased awareness of Lynch syndrome among
patients with UC, particularly tumors of the upper uri-
nary tract, is warranted as Lynch syndrome remains
underdiagnosed (Audenet et al., 2012; Catto et al.,
2003). Failure to recognize Lynch syndrome-associated
cases implies missed chances for genetic counseling,
surveillance programs for family members at increased
risk, and potential precision therapy with anti-PD-1
inhibition for MMR-deficient UC (Le et al., 2015).
Our findings suggesting that the predefined molecular
subtypes dominate over genetic predisposition also
emphasize the need to screen UC, or at least UTUC
for MMR-defective tumors to identify patients with
Lynch syndrome. Identified individuals diagnosed with
UC should probably be subjected to lifelong surveil-
lance, even if oncogenetic counseling based on gene
mutation and gender might modify the risk of a recur-
rent tumor (Therkildsen et al., 2017). How gene-muta-
tion carriers, especially MSH2, should be surveyed for
UC is currently not known, and different methods are
recommended; however, urinary cytology has a low
sensitivity (29%) and thus not sufficient (Myrhøj et al.,
2008).
Colorectal cancers that develop in Lynch syndrome
show a better disease-specific survival than sporadic
colorectal cancer, most likely due to the immunogenic
signatures in MMR-defective tumors (Boland, 2016;
Maccaroni et al., 2015). This hypothesis is further sup-
ported by the finding that MMR status predicts clini-
cal benefit from PD-1 blockade in colorectal cancer
(Le et al., 2015). The availability of immunotherapy
for patients with MMR-defective tumors offers new
hope in Lynch syndrome. Checkpoint inhibitors are
since 2016 also available in UC following the approval
of the PD-L1 inhibitor Atezolizumab in advanced UC
(Rosenberg et al., 2016).
This report represents the first molecular subtyping
of UC in Lynch syndrome and despite limited in size
represents a large collection of this rare tumor entity
with disease-predisposing MMR gene mutations/
MMR protein loss in concordance with the germline
mutation proven in 98% of the tumors. The MSI fre-
quency of 46% is comparable to other studies, sugges-
tive of a reduced sensitivity for this method in UC
with the currently available markers (Amira et al.,
2003). Study limitations relate to lack of data on dis-
ease-specific survival and limited availability of publi-
cally available data on gene expression signatures from
sporadic UTUC (Moss et al., 2017).
5. Conclusions
Urothelial carcinoma from patients with Lynch syn-
drome cluster according to MSI status, tumor loca-
tion, and tumor grade and within the molecular
subtypes established in sporadic UC. Urothelial-like
tumors predominate, which is consistent with the
pathological stage distribution. These data support
that application of novel molecular diagnostics and
targeted therapeutics developed in sporadic UC may
be relevant also for patients with Lynch syndrome.
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